Stocktoria
Q/C TECHNOLOGIES, INC. QCLS
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2008-07-24
Q/C TECHNOLOGIES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $3.5M | $3.4M | $7.9M | $9.1M | $6.7M |
| Operating income | -$9.8M | -$10.2M | -$17.1M | -$15.3M | -$28.8M |
| Net income | -$11.6M | -$23.4M | -$4.0M | -$15.2M | -$29.9M |
| EPS (diluted) | $-8.66 | $-1080.87 | $-5.33 | $-11.74 | — |
| Operating cash flow | -$9.1M | -$9.0M | -$13.0M | -$12.3M | -$19.5M |
| Cash & equivalents | $986,996 | $173,154 | $2.7M | $749,090 | $555,967 |
| Total assets | $41.2M | $21.4M | $17.9M | $17.5M | $24.8M |
| Total liabilities | $16.4M | $6.7M | $5.1M | $2.8M | $1.2M |
| Shareholders' equity | $21.8M | $9.8M | $12.4M | $14.7M | $23.6M |
Source: SEC EDGAR filings · CIK 0001321834 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.